Two randomized clinical trials of 5.988 (EMPEROR-Preserved) and 6.263 (DELIVER) patients with HFpEF showed that the SGLT-2 inhibitors empaglifozin and dapaglifozin significantly reduce the primary composite endpoint of hospitalization for heart failure and cardiovascular death [15, 49, 57]. The gene discussed is SLC5A2; the disease is heart failure.